The objective of this work is to describe the pro®le of prevalent and incident populations suffering from lower urinary tract symptoms (LUTS) suggestive of benign prostatic obstruction (BPO) and to analyse the management of care by 620 general practitioners (GPs) in France in 1997 and 1998. Patient records were extracted from the THALES database. Special attention was given to the use of medical therapy and switch rates (ie change to another or combination with another drug). In real life practice (RLP) French GPs predominantly utilise a 1 -adrenoceptor antagonists for the treatment of LUTS. This is in agreement with available evidence from randomised controlled trials (RCTs) with different medical therapies (a 1 -adrenoceptor antagonists, ®nasteride, plant extracts). On the contrary, the relatively high usage of phytotherapy might be explained by traditional and personal preferences. Using purely descriptive statistics, newer a 1 -adrenoceptor antagonists, alfuzosin and tamsulosin, seem to be the most frequently prescribed medical therapy for new patients and are, moreover, associated with a low switch rate. Prostate Cancer and Prostatic Diseases (2001) 4, 124±131.
Introduction
Symptomatic benign prostatic hyperplasia (BPH), nowadays referred to as lower urinary tract symptoms (LUTS) suggestive of benign prostatic obstruction (BPO), occurs frequently in elderly men. For example, the prevalence of urinary symptoms was studied in France in 1992 in a community-based, nation-wide, representative sample of 2011 French men 50 to 80-y-old, using the I-PSS questionnaire. 1 The data revealed that 85.8% of the investigated men had mild LUTS (including 18.8% with an I-PSS score of 0), and 14.2% had moderate or severe LUTS. Based on the obtained data, the authors estimated that 1.14 million French men had moderate to severe urinary symptoms that were likely to be associated with BPO.
In the past, surgery was the only treatment available for LUTS suggestive of BPO, next to the policy of watchful waiting (WW) where the patient is monitored by the physician at regular intervals but receives no active intervention. Today, patients suffering from LUTS are offered a wide variety of different treatment options, both surgical and medical. No existing therapy is perfect and it is the physician's task to understand the advantages and disadvantages of every treatment strategy and to choose the most appropriate option that best suits the patient's individual priorities. In order to understand the bene®ts and harms of the available treatment strategies, it is important to have knowledge of the evidence available from randomised controlled trials (RCTs). Quite often though there is a gap between`rational' evidence-based management and what happens in real life practice (RLP) .
Large scale RCTs have demonstrated superior ef®cacy of a 1 -adrenoceptor antagonists over placebo. 2 The same applies for the 5a-reductase inhibitor ®nasteride for patients with prostates larger than 40 g. 3 Furthermore, three independent direct comparative studies showed greater ef®cacy of a 1 -adrenoceptor antagonists than ®nas-teride. 4 ± 7 On the contrary, only a limited number of placebo-controlled studies concerning the ef®cacy of plant extracts using up-to-date methodology have been executed with b-sitosterol. 8, 9 In addition, the ef®cacy of the phytotherapeutic Serenoa repens seems to be comparable to that of ®nasteride. 10 The fact, however, that this trial did not include a placebo group and that the ef®cacy of ®nasteride over placebo is questioned in patients with small prostates 3,7 makes these study results less convincing. 11 Within the group of the a 1 -adrenoceptor antagonists (alfuzosin, doxazosin, prazosin, tamsulosin and terazosin), the prostate selective a 1 -adrenoceptor antagonist tamsulosin appears to have similar ef®cacy but to interfere less with blood pressure regulation than the other a 1 -adrenoceptor antagonists. 12 Unfortunately there is still very little information about men with LUTS seeking medical care in RLP and their subsequent management. In the French national community-based survey in 1992, mentioned above, the authors found that 8.3% of men had a diagnosis of LUTS of which 6.9% had undergone prostate surgery and 61% were treated medically. 1 It is also striking that during the last years the incidence of surgery declined considerably, with a parallel growth in the use of medical therapeutics such as a 1 -adrenoceptor antagonists and ®nasteride since the early 1990s. 13, 14 General practitioners (GPs) play quite an important role in the diagnosis and the management of LUTS suggestive of BPO in France. 14 A study executed in 1998 by the Association France d'Urologie (AFU) involving 3500 men aged 60 y or over indicates that 64% of men bothered by LUTS initially visit their GP and only 36% directly seek healthcare from a specialist (urologist or general surgeon). 14 It also appears that 80% of all medical scripts in France are prescribed by a GP, while only 12.5% come from a urologist and 7.5% from another specialist. 14 As GPs are to a large extent involved in the initial management of LUTS suggestive of BPO, the present historical database study aims to provide more insight into the occurrence and current management of this condition by GPs in real life practice in France. By means of analysis of patient ®les, we wish to verify whether the utilised treatment strategies are in line with scienti®c evidence obtained in RCTs.
Methods
To describe the pro®le of the population suffering from LUTS and the current management of these patients in real life practice in France, patient records of 620 GPs were extracted from the THALES database. The observation period was for 32 months (from September 1996 to April 1999).
THALES is an Epidemiological Observatory in France, based on a nation-wide representative sample including more than 600 computerised GPs, providing longitudinal observational data of the patients included in the practices (ie year of birth, sex, dates of visits, diagnoses and symptoms, prescriptions, general health indicators and occurrence of complications). Data are sent electronically and managed in an anonymised way, in line with recommendations of the Con®dentiality Data Authority (Commission Nationale de l'Informatique et des Liberte Âs; CNIL) and the National Council of Physicians (Conseil National de l'Ordre des Me Âdecins; CNOM). The database contains`common medical practice' data, involving approximately 1 million patient ®les followed for several years.
The results were computed on a yearly basis within the period of observation. Both prevalence and incidence data on LUTS suggestive of BPO have been extracted from the database. On the prevalent LUTS cases (all LUTS cases during a speci®c year), especially population pro®le analyses were performed; on the incident cases (all new diagnoses in a speci®c year), population pro®le analyses as well as management of care analyses were executed.
A LUTS case was considered as a treated LUTS case, if the patient had received a medical prescription for LUTS suggestive of BPO. A treated LUTS case is selected as one with a follow-up period !12 months if the patient ®le included either two GP visits with an interval of 12 months or more, or two visits with an interval of 10 months and a latest visit which took place after 30 March 1999.
The results of the observations are given using purely descriptive statistics. 
Results

Prevalence
Incidence
The number of newly diagnosed LUTS cases among 620 GPs in 1997 and 1998 was, respectively 3094 and 2532 patients ( Table 2 ). This implies that approximately 30% of all LUTS cases were newly diagnosed in 1997 whereas this decreased to 22% in 1998. On average, each GP saw 4.2 new patients with LUTS in 1998. The mean age of the newly diagnosed LUTS cases was about 68 y and the mean BMI 26 kg/m 2 . 
Co-morbidity
Around 40% of patients with LUTS suggestive of BPO suffered from hypertension, while approximately 15% had coronary heart disease (CHD) ( Tables 1 and 2 ).
Assessments
During the period of one year before the diagnosis of LUTS, 25.2% of the incident cases had prostate speci®c antigen (PSA) assessed in 1998, while 18.0% had a prostate ultrasound.
Management of prevalent cases
Of all diagnosed LUTS patients, only 59.6% were treated with medication by their GP in 1997 while the other 40.4% was offered a WW strategy; in 1998 these percentages were, respectively 56.5% for medical therapy and 43.5% for WW (Table 1 ).
In 1997, alfuzosin was the most frequently used medical treatment for LUTS by GPs, followed by Serenoa repens and ®nasteride (prescription share b20%; Figure  1 ). The next year, alfuzosin, Serenoa repens, ®nasteride as well as tamsulosin had a share of b20% in the total use of medical compounds for the treatment of LUTS.
Considering the three different therapeutic classes, 49.9% of the treated patients received an a 1 -adrenoceptor antagonist in 1997, a percentage that even augmented to 52.3% in 1998. The shares of ®nasteride and plant extracts in the medical treatment of LUTS were smaller and even decreased in 1998 compared to 1997 (®nasteride: 23.3% vs 23.5%, plant extracts: 39.7% vs 44.9%).
Management of incident cases
In 1997, 2041 of the 3094 incident cases (66.0%) received a prescription, while 1053 (34.0%) did not receive any treatment (WW); 1738 patients were treated in 1998 (68.6%) against 794 untreated cases (31.4%). Of these 1738 treated incident LUTS cases 474 (27.3%) had a follow-up of at least 12 months (Table 2) .
When considering the initial drug treatment, most GPs in 1997 prescribed alfuzosin (22.7% of the treated cases), followed by Serenoa repens (21.7%) and tamsulosin (19.8%) (Figure 2a ). In 1998 however, tamsulosin was the most frequently applied drug (21.6%), followed by Serenoa repens, alfuzosin and ®nasteride (20.4%, 17.7% and 17.4%, respectively). Next to tamsulosin, also the use of terazosin and ®nasteride increased in 1998 compared to 1997. Considering only those patients with a follow-up !12 months in 1998, tamsulosin and alfuzosin had a smaller percentage of use compared with all treated incident cases in 1998 (tamsulosin: 17.5% vs 21.6%; alfuzosin: 17.1% vs 17.7%). Figure 1 Distribution of medical treatment of LUTS suggestive of BPO of the prevalent cases (some patients may have received more than one drug).
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In both 1997 and 1998, most of the treated newly diagnosed LUTS patients received an a 1 -adrenoceptor antagonist as initial treatment strategy (1997: 45.6%; 1998: 47.3%), followed by phytotherapy (1997: 36.9%; 1998: 33.5%) and ®nasteride (1997: 15.1%; 1998: 17.4%) (Figure 2b ).
Referral to urology
Only 41 patients of the 2532 (1.6%) newly diagnosed LUTS cases in 1998 were referred to a medical urologist or a urology surgeon between their diagnosis and their ®rst prescription for LUTS. Furthermore, in total 128 cases (5.1%) were referred to a specialist after their diagnosis.
Time interval to ®rst prescription
In 1998, 1459 patients (83.9% of the treated incident population) received a prescription immediately after diagnosis of LUTS (time interval between diagnosis and script 0 days), while 279 patients (16.1%) received a prescription later on.
Treatment duration
All the medical treatments had a predominantly continuous drug-prescribing pattern (Table 3 ). Terazosin and ®nasteride had a higher percentage of continuous prescribing (70.0%, respectively 68.1%) than the other Table 4) . The prescription length of ®nasteride and the plant therapies was in the range of that of the other a 1 -adrenoceptor antagonists alfuzosin and tamsulosin.
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Dosage regimen
Of all the different medical therapies, only tamsulosin was always prescribed in a ®xed dose of 0.4 mg/day. The mean dose applied for alfuzosin was 8.55 mg/day (range 2.5 ± 10), for terazosin 3.53 mg/day (range 1 ± 5) and for ®nasteride 5.03 mg/day (range 5 ± 10).
Switch rates
A detailed analysis of the switches from the initially prescribed medical therapies to another compound in 1998 is given in Table 5 . Tamsulosin had the lowest switch rate: only 14.4% of the LUTS patients who received tamsulosin as ®rst medical treatment switched to another treatment option. If there was a switch from tamsulosin, Serenoa repens was mostly prescribed (4.8%), followed by alfuzosin (3.7%) and ®nasteride (3.5%). The switch from other medical therapies than tamsulosin resulted most of the time in prescription of tamsulosin. Terazosin showed the largest switch rate (26.5%). The overall treatment group difference approached statistical signi®cance (P`0.06). If phytotherapy was not considered in the analysis, as a test for comparison with other European countries where plant extracts are not prescribed, the overall treatment group difference was getting more signi®cant (P`0.01).
Discussion
LUTS suggestive of BPO is a highly prevalent diagnosis among older males in France as the present study results from 1998 show that a total of 620 GPs manage more than 11 000 patients with LUTS in their practice of whom around 2500 are newly diagnosed. In agreement with this observation, the results from a previous survey suggest that 1.14 million French men have moderate to severe LUTS suggestive of BPO. 1 Moreover, the increase of LUTS prevalence is not surprising, since the population is ageing in the developed nations and consequently more older men require treatment for LUTS. 13 The percentage of patients with speci®c co-morbidity in RCTs is not always representative for real life practice due to the fact that many patients are not included because of strict exclusion criteria. The present study suggests that approximately 40% of the LUTS patients in France suffer from hypertension, which is higher than the percentages reported in RCTs (about 20 ± 30%). 15 To exclude prostate cancer in patients with urinary problems, GPs often use prostate ultrasound, assess prostate speci®c antigen (PSA) or carry out a digital rectal examination (DRE). 14 A survey executed in 1995 in France reveals that 31% of the GPs who investigate micturition disorders use prostate ultrasound and 26% assess PSA. 14 Our observational study however, shows that more patients received a PSA investigation than a prostate ultrasound (25.2% vs 18% in 1998).
Strict of®cial guidelines for GPs and urologists for the management of LUTS suggestive of BPO are not available in France. One RMO (Re Âfe Ârences Me Âdicales Opposables) however contraindicates combination therapy. 16 `T reatment of benign prostatic hyperplasia: there is no justi®ca-tion for the use of a combination of two or more drugs to treat the disorders of micturition associated with benign prostatic hypertrophy.' Especially from a cost-effectiveness point of view, a combination of different drugs would not seem to be justi®ed.
Many patients with LUTS seem to be under medical supervision but do not receive any medical or surgical treatment (43.5% of French patients in 1998). They are offered the watchful waiting strategy, which is accepted as a management option by the 4th International Consultation on BPH as long as the patient has not developed Table 3 Patterns of drug prescribing in 1998 in the treated incident LUTS cases with a follow-up !12 and the same compound (n 363; 111 cases had a switch from the initial compound during their treatment) Interrupted: patient with only one script. Continuous: time interval between data of the end of a script period and the following one was always`3 months. Intermittent: time interval between data of the end of a script period and the following one was at least b3 months. one of the imperative indications for surgery. 17 The proportion of patients who decide, in dialogue with their GP, to use this kind of strategy decreased slightly in 1998 compared to 1997. The prevalent percentages of WW are greater than the incident ones (43.5 vs 31.4% for 1998), so it appears that proportionally more newly diagnosed LUTS cases receive and take medication than previously diagnosed patients. Some patients seem to stop taking medication after a while and switch from their treatment to WW (approximately 25%). Although this historical database study does not provide insight into the type of patients receiving WW, it may be speculated that it pre-dominantly concerns patients with mild LUTS and/or those not very bothered by their symptoms. It may however be argued that patients who seek medical advice for LUTS are at least to some extent bothered, as they would otherwise not visit their GP. Although the negative result of a thorough investigation may reassure and satisfy some of these patients, many patients that seek medical advice for LUTS might prefer/ expect active intervention provided it is ef®cacious and well tolerated. In addition, preliminary short-term (1.5 y) results indicate that patients who receive no treatment have a higher incidence of prostatic surgery and catheterisation and the interval between the ®rst symptom and either surgery or catheterisation was shorter than the men who had medical treatment. 18 This should be con®rmed by longer-term data. The THALES data show that a 1 -adrenoceptor antagonists are the most commonly used treatment option for LUTS suggestive of BPO among French GPs and their usage continues to grow (52.3% of treated prevalent cases in 1998 vs 49.9% in 1997) (Figures 1 and 2b) . Finasteride is prescribed in fewer cases but seems to have a small increase in prescription growth in new LUTS patients (17.4% in 1998 vs 15.1% in 1997). Plant extracts are used frequently, but their use is declining slightly (33.5% of treated prevalent cases in 1998 vs 36.9% in 1997). The question is whether these ®ndings in real life practice are in line with available evidence from RCTs.
According to the 4th International Consultation on BPH, 17 both a 1 -adrenoceptor antagonists and ®nasteride are acceptable medical treatment options for LUTS suggestive of BPO in patients who have not developed serious complications. In the case of ®nasteride however, the drug is only considered effective and acceptable in those men who also have clinically enlarged prostate (ie prostate size b40 g). 3, 17 Moreover, large RCTs have demonstrated superior ef®cacy of a 1 -adrenoceptor antagonists over placebo, 2 whereas three direct comparative studies showed that a 1 -adrenoceptor antagonists had superior effects over ®nasteride and that ®nasteride did not produce greater ef®cacy than placebo. 4 ± 7 The more common use of a 1 -adrenoceptor antagonists than ®nasteride is consequently in agreement with the results from RCTs.
Phytotherapy has not (yet) been considered an established treatment option by the 4th International Consultation on BPH, since there are few placebo-controlled trials and long-term trials are still lacking. 17 However, plant extracts such as Serenoa repens and Pygeum africanum are registered and reimbursed 14 in France, next to a 1 -adrenoceptor antagonists and ®nasteride. This is because plant extracts were registered a long time ago for the treatment of LUTS in some European countries among which France as well as Germany, Italy, Poland and Spain. 19 However, comparative study results are not very commended about phytotherapy. The ef®cacy of Serenoa repens appears to be similar to that of ®nasteride, 10 but the fact that the ef®cacy of ®nasteride over placebo has been questioned, 4 makes the results of this comparative study, which lacked a placebo arm to demonstrate superior ef®cacy of both Serenoa repens and ®nasteride over placebo, less impressive. 11 Two other comparative studies 20, 21 between an a 1 -adrenoceptor antagonist and a phytotherapeutic agent have shown that at least in the short-term, a 1 -adrenoceptor antagonists appear to improve symptoms better. Despite this evidence from RCTs, phytotherapy is still used frequently by GPs, probably because of tradition and personal preferences.
The fact that the use of ®nasteride in the incident cases has increased in 1998 compared to 1997 may be due to the positive results of studies presented in 1997 ± 1998, 22, 23 which claim that long-term medical treatment with ®nasteride reduces the probability of surgery and acute urinary retention. Similar long-term studies with a 1 -adrenoceptor antagonists have not been ®nalised until now. It can however be expected that similar results will be obtained, since two relatively short-term comparative studies (6 ± 12 months) between ®nasteride and a 1 -adrenoceptor antagonists indicate that a 1 -adrenoceptor antagonists are at least as good as ®nasteride in terms of disease progression, ie reduction of the development of acute urinary retention and/or the need for surgery. 5, 6 Within the group of a 1 -adrenoceptor antagonists, alfuzosin is the most prescribed compound among French GPs in prevalent LUTS cases, but tamsulosin prescription growth may indicate that it will soon take the leading position in the future (Figures 1 and 2a) . Tamsulosin already is the most frequently prescribed drug in new LUTS patients in 1998. Tamsulosin was also associated with a low switch rate, much lower (14.4%) than that of, for instance, terazosin (26.5%). The high usage and low switch rate of tamsulosin may be related to its prostate speci®c pro®le. It has been demonstrated that tamsulosin has comparable ef®cacy to other a 1 -adrenoceptor antagonists (eg terazosin, alfuzosin) but exerts marginal interference with blood pressure regulation and related adverse events. 12,24 ± 31 It also has a lower potential to induce symptomatic orthostatic hypotension than terazosin during nocturial or early morning orthostatic stress testing when administered according to prescribing information. 31 Comparison of the prescription attitude of GPs, re¯ected in the LUTS treatment distribution of prevalent cases in 1998 (increasing tamsulosin use; a 1 -adrenoceptor antagonists: 52.3%; phytotherapy: 39.7%; ®nasteride: 23.3%), and IMS (Information Me Âdicale et Statistique) data shows a fair correlation between the two. The market data in value for medical therapy in France show that the a 1 -adrenoceptor antagonists are the most frequently prescribed medical treatment option for LUTS in 1998 (45.3% market share), followed by phytotherapy (37.5%) and ®nasteride (17.2%). 14 Within the a 1 -adrenoceptor antagonist market, most of the increase in prescriptions for a 1 -adrenoceptor antagonists in the period 1994 ± 1998 is derived from yearly increases in the number of patients receiving tamsulosin that was introduced in 1996. 14 The data also show that the number of patients treated with alfuzosin remained fairly stable, that the market share of ®nasteride is decreasing slowly and that phytotherapy is still used frequently although its usage is decreasing. This indicates that the results obtained in the present sample of 620 GPs seem to be representative for France as a whole.
In conclusion, the study results concerning the treatment approach for LUTS suggestive of BPO in RLP in France show some correlation but also differences with results obtained in RCTs as the treatment approach is not always consistent with the scienti®c evidence (eg high usage of plant extracts). This indicates that the in¯uence of the GP's personal preferences on treatment choice is considerable and probably explains the gap between rational evidence-based management and actual prescribing behaviour. A study executed in The Netherlands asserts that this statement is in every way valid among urologists. 32 
